Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy
Qianmei Yang, Gang Shi, Xiaolei Chen, Yi Lin, Lin Cheng, Qingyuan Jiang, Xi Yan, Ming Jiang, Yiming Li, Hantao Zhang, Huiling Wang, Yuan Wang, Qingnan Wang, Yujing Zhang, Yi Liu, Xiaolan Su, Lei Dai, Minghai Tang, Li Jia, Lan Zhang, Zhiyong Qian, Dechao Yu, Hongxin Deng
Abstract
Our results provide systemic insights into the immune-regulation ability of PTX to induce ICD, which acts as an inducer of endogenous vaccines through ICD effects, and also provides an experimental basis for clinical combination therapy with nano-PTX and PD-1 antibodies.
Topics & Concepts
PaclitaxelImmunotherapyImmune systemCancer researchPharmacologyChemistryMedicineImmunologyCancerInternal medicineNanoplatforms for cancer theranosticsCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses